Top Page
Bristol-Myers Squibb
(NYSE:BMY)
Bristol-Myers Squibb (BMY) vs. SPDR S&P 500 ETF (SPY)
Bristol-Myers Squibb Business Overview & Revenue Model
Bristol-Myers Squibb Key Performance Indicators (KPIs)
Analyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating how well the company diversifies its income streams.
Main Street DataBristol-Myers Squibb Earnings Call Summary
Bristol-Myers Squibb Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.70B | 48.30B | 45.01B | 46.16B | 46.38B | 42.52B |
| Gross Profit | 29.45B | 27.43B | 25.36B | 26.49B | 26.76B | 21.70B |
| EBITDA | 15.09B | 3.17B | 19.37B | 19.22B | 20.12B | 4.93B |
| Net Income | 5.05B | -8.95B | 8.03B | 6.33B | 6.99B | -8.99B |
Balance Sheet | ||||||
| Total Assets | 94.68B | 92.60B | 95.16B | 96.82B | 109.31B | 118.48B |
| Cash, Cash Equivalents and Short-Term Investments | 13.60B | 10.86B | 12.28B | 9.25B | 17.22B | 16.45B |
| Total Debt | 50.93B | 51.20B | 41.46B | 40.72B | 45.60B | 51.67B |
| Total Liabilities | 77.19B | 76.22B | 65.67B | 65.70B | 73.31B | 80.60B |
| Stockholders Equity | 17.43B | 16.34B | 29.43B | 31.06B | 35.95B | 37.82B |
Cash Flow | ||||||
| Free Cash Flow | 14.58B | 13.94B | 12.65B | 11.95B | 15.23B | 13.30B |
| Operating Cash Flow | 15.90B | 15.19B | 13.86B | 13.07B | 16.21B | 14.05B |
| Investing Cash Flow | -1.39B | -21.35B | -2.29B | -1.06B | -538.00M | -10.86B |
| Financing Cash Flow | -8.32B | 5.13B | -9.42B | -16.96B | -16.22B | -1.15B |
Bristol-Myers Squibb Technical Analysis
Bristol-Myers Squibb Risk Analysis
Bristol-Myers Squibb Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $150.06B | 24.06 | 33.26% | 2.61% | 3.69% | 501.26% | |
| ― | $140.77B | 13.17 | 12.16% | 6.90% | 14.72% | ― | |
| ― | $218.53B | 13.49 | 35.44% | 3.68% | 2.00% | 20.01% | |
| ― | $86.97B | 19.90 | 23.04% | 3.76% | 3.46% | -13.29% | |
| ― | $157.07B | 23.87 | 99.14% | 3.23% | 13.10% | 110.67% | |
| ― | $89.21B | 17.69 | 29.31% | 5.72% | 2.57% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Bristol-Myers Squibb Corporate Events
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1)’. The study aims to assess the efficacy and safety of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, a significant step in addressing mental health challenges.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%. The study aims to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with chemotherapy in treating advanced non-squamous non-small cell lung cancer with PD-L1 expression ≥ 1%.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia. The study aims to assess the efficacy and safety of KarXT in Japanese adults with acute psychosis due to schizophrenia, highlighting its potential significance in addressing mental health challenges.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2 study titled A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in Adolescent Participants With Alpha (α)-Thalassemia. The study aims to assess the efficacy and safety of luspatercept in treating anemia in adults with α-thalassemia hemoglobin H disease and to evaluate safety and drug levels in adolescents. This study is significant as it could offer new treatment options for this genetic blood disorder.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 open-label extension study titled ‘A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer’s Disease (ADAGIO-3)’. The study aims to assess the long-term safety and effectiveness of the drug combination KarXT and KarX-EC in treating agitation in Alzheimer’s patients who have completed previous related studies. This research is significant as it addresses a critical need for effective treatments for agitation in Alzheimer’s disease.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer’s Disease (MINDSET 1).’ The study aims to assess the efficacy and safety of the drug combination KarXT + KarX-EC in treating cognitive impairment in Alzheimer’s patients, a significant area of unmet medical need.
Study Overview: Bristol-Myers Squibb Company is initiating a study titled ‘Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU).’ The study aims to assess treatment satisfaction and preferences among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy. This research is significant as it seeks to provide insights into patient satisfaction with this treatment, potentially influencing prescribing practices and patient outcomes.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 clinical study titled A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer. The study aims to evaluate the efficacy of BMS-986500 both as a standalone treatment and in combination with other drugs for patients with advanced solid tumors and breast cancer. This research is significant as it explores new therapeutic options for challenging cancer types.
In a significant development, Bristol-Myers Squibb Company is conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease. The study aims to assess the safety and efficacy of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a condition that significantly impacts patient quality of life and caregiver burden.
Study Overview: Bristol-Myers Squibb Company has completed a study titled Real-world Utilization Patterns, Clinical Outcomes, and HCRU in Lower-risk MDS Patients Treated With Luspatercept: A Multinational Medical Record Review Study. The study aimed to understand the treatment use of luspatercept in adults diagnosed with lower-risk myelodysplastic syndromes (MDS), providing insights into treatment patterns and healthcare resource utilization.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 trial titled A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). The study aims to compare the efficacy and safety of a new drug combination, BMS-986489, against an existing treatment, Atezolizumab, for patients with extensive-stage small cell lung cancer.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis.’ The study aims to assess the effectiveness, safety, and tolerability of the drug BMS-986278 in treating progressive pulmonary fibrosis, a condition that leads to scarring of the lungs and affects breathing.
Bristol-Myers Squibb Company is conducting a Phase 3 study titled ‘EXCALIBER-Maintenance’ to evaluate the effectiveness of iberdomide maintenance therapy compared to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplantation. The study aims to determine which treatment offers better outcomes for patients, potentially setting a new standard in maintenance therapy for this condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-2).’ The study aims to assess the safety and effectiveness of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern due to its impact on patient quality of life and caregiver burden.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)’. The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in individuals with moderate to severe SLE, a chronic autoimmune disease.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 trial titled Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3). The study aims to evaluate the efficacy and safety of repotrectinib compared to crizotinib in treating this specific type of lung cancer, which is significant for advancing treatment options for patients who have not previously received TKI therapy.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial, titled ‘ELEMENT-MDS,’ to evaluate the efficacy and safety of Luspatercept compared to Epoetin Alfa in treating anemia in patients with very low, low, or intermediate-risk Myelodysplastic Syndrome (MDS) who have not previously received erythropoiesis-stimulating agents and are not dependent on blood transfusions. This study aims to provide insights into alternative treatments for MDS-related anemia, potentially improving patient outcomes.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion.’ The study aims to assess the safety and effectiveness of BMS-986504, a selective PRMT5 inhibitor, in treating pancreatic cancer patients with a specific genetic deletion.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1).’ The study aims to assess the effectiveness and safety of KarXT in treating manic episodes in patients with Bipolar-I Disorder, a significant area of unmet medical need.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2 clinical study titled A Phase 2, Study for the Treatment of Anemia With Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents. The study aims to assess the efficacy and safety of luspatercept in treating anemia in adult patients with α-thalassemia hemoglobin H disease and to evaluate its safety and pharmacokinetics in adolescents. This research is significant as it addresses a critical need for effective treatments in this patient population.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia. The study aims to assess the efficacy and safety of KarXT in treating acutely psychotic Japanese adults with schizophrenia, a condition with significant impact on mental health.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer’s Disease (MINDSET 1)’. The study aims to assess the efficacy and safety of the drug combination KarXT + KarX-EC in treating cognitive impairment in patients with mild to moderate Alzheimer’s Disease, a significant area of unmet medical need.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)’ to assess treatment satisfaction among adults with schizophrenia in the U.S. prescribed xanomeline and trospium chloride (X/T) therapy. This study aims to provide insights into patient preferences and satisfaction, which are crucial for improving treatment strategies.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-3)’. The study aims to assess the long-term efficacy and safety of the drug combination KarXT and KarX-EC in patients with Alzheimer’s-related agitation who have completed prior studies. This research is significant as it addresses a critical need for effective treatments for agitation in Alzheimer’s patients.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study to evaluate the efficacy of a combination treatment of Nivolumab and Relatlimab with chemotherapy compared to Pembrolizumab with chemotherapy. This study targets patients with stage IV or recurrent non-squamous non-small cell lung cancer exhibiting PD-L1 expression of 1% or higher. The study aims to establish a more effective first-line treatment option, which could significantly impact patient outcomes and treatment standards.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 clinical study titled ‘A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer.’ The study aims to evaluate the safety and efficacy of BMS-986500, both as a standalone treatment and in combination with other drugs, in patients with advanced solid tumors and breast cancer. This research is significant as it explores new treatment avenues for challenging cancer cases.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2). The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in patients with moderate to severe SLE, a chronic autoimmune disease. This research is significant as it could lead to a new treatment option for SLE patients.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease. The study aims to assess the safety and effectiveness of KarXT + KarX-EC in treating agitation in adults with Alzheimer’s Disease, a significant concern for patients and caregivers.
Study Overview: Bristol-Myers Squibb is conducting the ELEMENT-MDS trial, a Phase 3 study aimed at comparing the efficacy and safety of Luspatercept versus Epoetin Alfa in treating anemia in adults with very low, low, or intermediate-risk Myelodysplastic Syndrome (MDS) who are not receiving blood transfusions. This study is significant as it targets ESA-naïve participants, potentially offering a new therapeutic option for this patient group.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion. The study aims to evaluate the safety and efficacy of BMS-986504, a selective PRMT5 inhibitor, in combination with standard chemotherapy drugs in patients with a specific genetic deletion, potentially offering a new treatment avenue for this aggressive cancer.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)’. The study aims to assess the efficacy and safety of two drugs, repotrectinib and crizotinib, in treating patients with a specific type of lung cancer. This research is significant as it could lead to improved treatment options for NSCLC patients.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2 study titled A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and recommended doses of BMS-986340, alone and in combination with other drugs, for treating advanced solid tumors. This first-in-human study is significant as it explores new treatment avenues for challenging cancer types.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-2)’. The study aims to assess the safety and effectiveness of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern due to its impact on patient quality of life and caregiver burden.
Bristol-Myers Squibb Company (BMY) has announced a new clinical study aimed at evaluating the efficacy of BMS-986504 in combination with pembrolizumab and chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with homozygous MTAP deletion. This study, titled ‘A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion,’ seeks to determine the clinical benefits of this novel combination therapy.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-1).’ The study aims to assess the safety and efficacy of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern as it affects patient quality of life and caregiver burden.
The Pan-Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to evaluate the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This study is significant as it explores sustained treatment options for patients who have previously participated in Bristol-Myers Squibb (BMS) trials.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis. The study aims to assess the drug levels, efficacy, and safety of Deucravacitinib in children aged 4 to under 18 years with moderate to severe plaque psoriasis, highlighting its potential impact on pediatric dermatological treatments.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2A study titled A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF). The study aims to assess the safety and effectiveness of the drug BMS-986435/MYK-224 in treating patients with HFpEF, a condition with limited treatment options, highlighting its potential significance in cardiovascular therapy.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2a clinical study titled A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470. The study aims to assess the safety, tolerability, and preliminary efficacy of BMS-986470, a potential treatment for sickle cell disease, highlighting its significance in addressing this chronic condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)’. The study aims to evaluate the efficacy and safety of two drugs, repotrectinib and crizotinib, in treating patients with this specific type of lung cancer. This research is significant as it explores potential advancements in targeted cancer therapies.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2/3 clinical study titled A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy. The study aims to assess the effectiveness and safety of ozanimod in achieving and maintaining clinical remission in pediatric patients with moderate to severe ulcerative colitis who have not responded adequately to conventional treatments.
Study Overview: Bristol-Myers Squibb, in collaboration with Janssen Research & Development, is conducting a Phase 3 clinical trial titled A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation. The study aims to evaluate the efficacy and safety of milvexian, an oral Factor XIa inhibitor, compared to apixaban in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation. This study is significant as it explores a potentially new treatment option for a common heart condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3, open-label extension study titled ‘A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)’. The study aims to evaluate the long-term safety and tolerability of KarXT in treating manic episodes associated with Bipolar-I disorder, which is crucial for understanding the drug’s sustained impact on patients.
Study Overview: Bristol-Myers Squibb Company, in collaboration with Janssen Research & Development, LLC, is conducting a Phase 3 study titled A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome. The study aims to evaluate the efficacy and safety of Milvexian, an oral Factor XIa inhibitor, in reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular death, myocardial infarction, and ischemic stroke, compared to a placebo.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1)’. The study aims to assess the safety and effectiveness of Deucravacitinib, a promising treatment for Sjögren’s Syndrome, a chronic autoimmune disease. This research is significant as it could lead to a new therapeutic option for patients with limited treatment choices.
Bristol-Myers Squibb Company is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)’. The study aims to assess the effectiveness of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, a significant mental health condition.
Study Overview: Bristol-Myers Squibb Company initiated a study titled A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO). The study aimed to assess the safety and effectiveness of MYK-224 in treating obstructive Hypertrophic Cardiomyopathy, a condition characterized by thickened heart muscles that can obstruct blood flow.
The recent clinical study update from Bristol-Myers Squibb Company and Incyte Corporation, titled A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204), aims to evaluate the safety, tolerability, and efficacy of combining Epacadostat with Nivolumab in treating various advanced cancers. This study is significant as it explores potential new treatment combinations for challenging cancer types.
Pfizer and Bristol-Myers Squibb are conducting a study titled A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma. The study aims to evaluate the safety and tolerability of combining elranatamab and iberdomide for treating relapsed or refractory multiple myeloma, a challenging form of cancer that resists treatment or returns after improvement.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled ‘A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants.’ The study aims to evaluate the drug levels, tolerability, and biological availability of a single subcutaneous dose of BMS-986446 in healthy individuals, which could provide insights into its potential therapeutic applications.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis.’ The study aims to evaluate the long-term safety of the drug Deucravacitinib compared to Ustekinumab in individuals with psoriasis, a significant step in understanding treatment options for this condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2 study titled A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and recommended doses of BMS-986340, both alone and in combination with other drugs, for patients with advanced solid tumors. This first-in-human study is significant as it explores new treatment avenues for these challenging conditions.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2). The study aims to assess the efficacy of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, highlighting its potential significance in improving mental health treatments.
In a recent clinical study update, Bristol-Myers Squibb Company (BMY) is evaluating the efficacy and safety of Deucravacitinib in adults with active Sjögren’s Syndrome. Officially titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1)’, the study aims to assess the therapeutic potential of Deucravacitinib, a promising drug candidate, in treating this chronic autoimmune condition.
Study Overview: Bristol-Myers Squibb recently updated its clinical study titled A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO). The study aimed to assess the safety, efficacy, and tolerability of MYK-224 in patients with obstructive Hypertrophic Cardiomyopathy (oHCM), a condition that causes thickening of the heart muscle, leading to obstruction of blood flow.
Bristol-Myers Squibb Company has announced a new clinical study, titled ‘IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment.’ The study aims to evaluate the efficacy of Izalontamab Brengitecan compared to traditional platinum-based chemotherapy in patients whose cancer has progressed following immunotherapy. This research is significant as it explores new treatment avenues for metastatic urothelial cancer, potentially improving patient outcomes.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)’. The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in individuals with moderate to severe SLE, a significant autoimmune disease affecting multiple organs.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase IV postmarketing study titled ‘A Lactation Study in Women Receiving Treatment With Ozanimod.’ The study aims to evaluate the concentrations of ozanimod and its major metabolites in the breast milk of lactating women and assess the effects on breastfed infants. This research is significant as it provides insights into the safety and implications of ozanimod use during lactation.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis.’ The study aims to assess the effectiveness, safety, and tolerability of the drug BMS-986278 in treating idiopathic pulmonary fibrosis, a chronic lung disease with limited treatment options.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2/3 trial titled ‘IZABRIGHT-Bladder01,’ which aims to compare the effectiveness of Izalontamab Brengitecan against platinum-based chemotherapy for patients with metastatic urothelial cancer who have experienced disease progression following immunotherapy. This study is significant as it explores new treatment avenues for a challenging cancer type.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU).’ The study aims to assess treatment satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (XT) therapy. This research is significant as it seeks to provide insights into patient preferences and satisfaction with this specific treatment regimen.
In a recent clinical study update, Bristol-Myers Squibb Company (BMY) is conducting a Phase 3 trial titled ‘A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).’ The study aims to compare the efficacy and safety of the BMS-986489 combination therapy against Atezolizumab, both paired with Carboplatin and Etoposide, in treating extensive-stage small cell lung cancer.
Bristol-Myers Squibb’s recent earnings call painted a picture of both optimism and caution. The company showcased strong performance in its growth portfolio, which led to an increase in revenue guidance, reflecting confidence in its strategic direction. However, challenges such as unmet expectations in certain Phase III trials and the decline of its legacy portfolio were also acknowledged.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1). The study aims to assess the effectiveness and safety of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, highlighting its potential significance in improving mental health treatments.
Study Overview: Bristol-Myers Squibb is initiating a Phase 3 clinical study titled A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis. The study aims to assess the effectiveness, safety, and drug levels of Deucravacitinib, a promising treatment for adolescents suffering from moderate to severe plaque psoriasis.
Bristol-Myers Squibb Company (BMY) is conducting a Phase 1/2a study titled ‘A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adults with advanced solid tumors, marking a significant step in cancer treatment research.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With DSM-5 Schizophrenia.’ The study aims to assess the efficacy and safety of KarXT in treating acutely psychotic Japanese adults with schizophrenia, a significant step in addressing mental health challenges.
Bristol-Myers Squibb Company (BMY) is currently conducting a Phase 1b clinical study titled A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus. The study aims to assess the safety, tolerability, and drug effects of BMS-986326 in adults with various forms of lupus, which is significant for advancing treatment options for this challenging condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%. The study aims to compare the efficacy of Nivolumab and Relatlimab combined with chemotherapy against Pembrolizumab with chemotherapy in treating advanced non-squamous non-small cell lung cancer with PD-L1 expression ≥ 1%.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘SUCCESSOR-2’ to evaluate the efficacy of Mezigdomide in combination with Carfilzomib and Dexamethasone (MeziKD) versus Carfilzomib and Dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). The study aims to determine if the addition of Mezigdomide improves treatment outcomes, which could signify a significant advancement in RRMM therapy.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion.’ The study aims to evaluate the safety and effectiveness of BMS-986504, a selective inhibitor, in treating pancreatic cancer patients with a specific genetic deletion.
The Pan-Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to assess the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This study is significant as it explores the extended use of these treatments, potentially offering new insights into cancer management.
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, primarily in the sectors of oncology, immunology, and cardiovascular diseases.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis.’ The study aims to assess the effectiveness and safety of BMS-986278, a potential treatment for progressive pulmonary fibrosis, a condition characterized by scarring of lung tissue that leads to severe breathing difficulties.
Pfizer Inc. and Bristol-Myers Squibb Company are conducting a Phase 1B study titled ‘A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA.’ The study aims to evaluate the safety and tolerability of combining elranatamab with iberdomide in patients with relapsed or refractory multiple myeloma, a cancer affecting plasma cells.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3). The primary goal is to evaluate the long-term safety and tolerability of KarXT in treating manic episodes in Bipolar-I Disorder, a significant step in addressing mental health treatment needs.
Study Overview: Bristol-Myers Squibb is conducting a clinical study titled A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and optimal dosing of BMS-986340, both alone and combined with other drugs, in patients with advanced solid tumors. This first-in-human study is significant as it explores new treatment avenues for challenging cancer cases.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/1b clinical trial titled A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors. The study aims to assess the safety, tolerability, and efficacy of escalating doses of BMS-986463 in patients with select advanced malignant tumors, marking a significant step in cancer treatment research.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis. The study aims to assess the drug levels, efficacy, and safety of Deucravacitinib in children aged 4 to less than 18 years with moderate to severe plaque psoriasis, highlighting its potential significance in pediatric dermatology.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled ‘A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of BMS-986460 in men with this advanced form of prostate cancer, which is significant for developing new treatment options.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3b study titled ‘A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants.’ The study aims to evaluate the efficacy and safety of Luspatercept at its maximum approved dose in participants with low-risk Myelodysplastic Syndrome (LR-MDS) who require red blood cell transfusions. This study is significant as it addresses the treatment needs of patients with specific risk profiles, potentially improving their quality of life.
Study Overview: Bristol-Myers Squibb Company recently completed a post-marketing surveillance study titled ‘Empliciti® (Elotuzumab) Post-Marketing Surveillance Study for Patients With Multiple Myeloma in Taiwan.’ The study aimed to evaluate the safety of elotuzumab when used with pomalidomide and dexamethasone, and separately with lenalidomide and dexamethasone, in treating relapsed and refractory multiple myeloma (RRMM) in patients who had undergone prior therapies. This research is significant as it provides crucial safety data for these drug combinations in a real-world setting.
On July 31, 2025, Bristol Myers Squibb reported its financial results for the second quarter of 2025, highlighting a total revenue of $12.3 billion, a 1% increase from the previous year. The company’s Growth Portfolio revenues rose by 18%, driven by strong performances in its immuno-oncology products, while the Legacy Portfolio saw a decline due to generic competition and Medicare Part D impacts. The company raised its 2025 revenue guidance and emphasized its focus on advancing transformational medicines and pipeline opportunities to sustain long-term growth.
The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1)’. The study aims to assess the efficacy and safety of KarXT in treating manic episodes in patients with Bipolar-I Disorder, marking a significant step in addressing this challenging condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis. The study aims to assess the efficacy, safety, and drug levels of Deucravacitinib in adolescents suffering from this condition, which is significant for expanding treatment options in this age group.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2a study titled A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors. The study aims to assess the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adults with advanced solid tumors, marking a significant step in cancer treatment research.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%. The study aims to compare the efficacy of the Nivolumab and Relatlimab combination with chemotherapy against Pembrolizumab with chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1b study titled A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus. The study aims to assess the safety, tolerability, and effects of BMS-986326 in adults with various forms of lupus, marking a significant step in lupus treatment research.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia. The study aims to assess the efficacy and safety of KarXT in treating acutely psychotic Japanese adults with schizophrenia, a significant mental health condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The study aims to assess the effectiveness, safety, and tolerability of the drug BMS-986278 in treating progressive pulmonary fibrosis, a condition characterized by worsening lung function.
Study Overview: Bristol-Myers Squibb and Pfizer are conducting a Phase 1b study titled A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA. The study aims to evaluate the safety and tolerability of combining elranatamab and iberdomide in patients with relapsed or refractory multiple myeloma, a challenging form of cancer that returns after treatment or resists current therapies.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2 clinical trial titled A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent NSCLC. The study aims to assess the efficacy of two dosing regimens of Nivolumab, a subcutaneous formulation, in combination with Ipilimumab and chemotherapy for patients with untreated metastatic or recurrent non-small cell lung cancer (NSCLC). This study is significant as it explores new treatment combinations for a challenging cancer type.
On July 25, 2025, Bristol Myers Squibb announced the departure of Dr. Samit Hirawat, the Chief Medical Officer and Head of Development, effective November 1, 2025. Dr. Hirawat will transition to an advisory role starting August 1, 2025, and will receive severance benefits and prorated incentives. Concurrently, Dr. Cristian Massacesi will join the company as the new Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. Dr. Massacesi brings extensive experience from his previous roles at AstraZeneca and Alexion, and his appointment is expected to bolster Bristol Myers Squibb’s efforts in advancing its product pipeline and achieving regulatory approvals.
The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘POETYK SLE-1’ to evaluate the efficacy and safety of deucravacitinib in participants with active Systemic Lupus Erythematosus (SLE). The study aims to compare the drug’s effectiveness against a placebo in treating moderate to severe cases of SLE, a chronic autoimmune disease.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2/3 clinical study titled A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy. The study aims to assess the effectiveness and safety of oral Ozanimod in achieving and maintaining clinical remission in pediatric patients with moderate to severe ulcerative colitis who have not responded adequately to conventional treatments.
In a significant development, Bristol-Myers Squibb Company (BMY) is conducting a Phase 3 clinical study titled ‘A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)’. The primary goal is to assess the effectiveness of KarXT in alleviating manic symptoms in individuals with Bipolar-I disorder over a three-week inpatient period. This study is crucial as it aims to address the challenges faced by patients experiencing acute manic episodes.
Study Overview: Bristol-Myers Squibb is conducting a study titled A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion. The study aims to evaluate the safety and efficacy of BMS-986504, a selective PRMT5 inhibitor, in combination with standard chemotherapy drugs for treating a specific type of pancreatic cancer.
In a recent update, Bristol-Myers Squibb Company (BMY) announced the initiation of a Phase 2A clinical study titled ‘A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)’. The study aims to assess the safety and tolerability of BMS-986435/MYK-224, a promising treatment for patients suffering from HFpEF, a condition with limited therapeutic options.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease. The study aims to assess the safety and effectiveness of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern in managing the disease.
Bristol-Myers Squibb Company is conducting a clinical study titled ‘A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers.’ The study aims to evaluate the safety and efficacy of BMS-986253 combined with Nivolumab or Nivolumab plus Ipilimumab in patients with advanced cancers. This research is significant as it explores potential new treatment combinations for challenging cancer cases.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase 3 clinical trial titled Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3). The study aims to evaluate the efficacy and safety of repotrectinib compared to crizotinib in treating this specific type of lung cancer, which is significant for advancing treatment options for patients with this condition.
Bristol-Myers Squibb Company is conducting a Phase 1 clinical study titled ‘A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants.’ The study aims to assess the safety, tolerability, and pharmacokinetics of BMS-986419, as well as its impact on cardiac repolarization in healthy individuals. This research is significant as it explores the potential of BMS-986419 in a controlled environment, providing insights into its effects on heart function.
The Pan Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to evaluate the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This study is significant as it seeks to provide insights into the prolonged effects and safety of these treatments, potentially influencing future cancer therapies.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘SUCCESSOR-2’ to evaluate the efficacy of Mezigdomide in combination with Carfilzomib and Dexamethasone (MeziKD) versus Carfilzomib and Dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). The study aims to determine if the addition of Mezigdomide can improve treatment outcomes, which is significant for advancing therapeutic options for RRMM.
Study Overview: Bristol-Myers Squibb is conducting a study titled A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment. The study aims to evaluate the efficacy and safety of Izalontamab Brengitecan, a bi-specific antibody-drug conjugate, compared to standard chemotherapy options in patients with specific types of breast cancer.
Bristol-Myers Squibb Company is currently conducting a Phase 3 clinical study titled A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance). The study aims to evaluate the effectiveness of iberdomide maintenance therapy compared to lenalidomide in patients with newly diagnosed multiple myeloma following an autologous stem cell transplant. This research is significant as it could potentially lead to improved maintenance therapy options for multiple myeloma patients.
Bristol-Myers Squibb Company (BMY) is currently conducting a Phase 3 study titled A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1). The study aims to assess the safety and efficacy of Deucravacitinib, a drug intended to treat adults with active Sjögren’s Syndrome, a chronic autoimmune condition. This study is significant as it could lead to a new treatment option for this challenging condition.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase 1 study titled A Phase 1 Open-Label, Multi-Center Study to Evaluate Pharmacokinetics, Safety and Tolerability of BMS-986504 in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion. The study aims to assess the safety, tolerability, and drug levels of BMS-986504 in participants with advanced solid tumors, highlighting its significance in potentially advancing cancer treatment options.
Bristol-Myers Squibb Company (BMY) recently completed a study titled ‘Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan.’ The study aimed to evaluate the quality of life in patients with hypertrophic cardiomyopathy, a condition characterized by the thickening of the heart muscle, in Japan. This research is significant as it provides insights into the patient experience and potential areas for therapeutic intervention.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)’. The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in treating moderate to severe Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants With Early Alzheimer’s Disease (TargetTau-1)’. The study aims to assess the effectiveness, safety, and tolerability of the drug BMS-986446 in treating early Alzheimer’s disease, a significant step in addressing this challenging condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1). The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in individuals with moderate to severe SLE, a chronic autoimmune disease. This research is significant as it could lead to a new therapeutic option for SLE patients.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2). The study aims to assess the effectiveness of KarXT in managing manic episodes in individuals with Bipolar-I Disorder, highlighting its potential significance in improving treatment options for this condition.
Bristol-Myers Squibb Company (BMY) has launched a significant clinical study titled A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer. The study aims to evaluate the efficacy and safety of Izalontamab Brengitecan, a bi-specific antibody-drug conjugate, compared to standard chemotherapy options for patients with advanced triple-negative breast cancer who are not eligible for anti-PD(L)1 therapies.
Bristol-Myers Squibb Company is conducting a Phase 3 clinical study titled ‘A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-1).’ The study aims to assess the safety and effectiveness of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern for both patients and caregivers.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2/3 study titled ‘A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy.’ The study aims to assess the effectiveness and safety of ozanimod in achieving and maintaining clinical remission in pediatric patients with moderate to severe ulcerative colitis who have not responded adequately to conventional treatments.
Study Overview: Bristol-Myers Squibb recently completed a study titled ‘Real World Outcomes of Nivolumab + Relatlimab in Patients With Advanced Melanoma in the Flatiron Database.’ The study aimed to evaluate the real-world clinical outcomes for patients with advanced melanoma treated with various therapies, including the combination of Nivolumab and Relatlimab. This research is significant as it provides insights into the effectiveness of these treatments outside of controlled clinical trials.
The Pan Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to evaluate the long-term safety of nivolumab, both as a monotherapy and in combination with other cancer treatments, across various tumor types. This study is significant as it seeks to provide insights into the sustained efficacy and safety of these treatments, potentially influencing future cancer therapy protocols.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2A study titled ‘A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)’. The study aims to assess the safety and tolerability of BMS-986435/MYK-224 in individuals with HFpEF, a condition with limited treatment options, highlighting its potential significance in addressing a critical unmet medical need.
In a significant development, Bristol-Myers Squibb Company (BMY) has announced a new clinical study titled ‘A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion.’ The study aims to evaluate the safety and efficacy of BMS-986504, a selective MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel and Gemcitabine for treating patients with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous MTAP deletion.